Progress fibrinolysis tumor necrosis factor infusions humans Concomitant increase tissue-type plasminogen activator plasminogen activator inhibitor fibrin ogen degradation products Several investigators tumor necrosis factor TNF production plasminogen activator plasminogen activators PAs endothelial cells vitro vivo effects recombinant human TNF administration fibrinolysis parameters plasma period continuous TNF infusion cancer patients active disease plasma levels PAI activity sevenfold hours TNF infusion result increase antigen antigen detectable Plasma concentrations tissue-type PA t-PA antigen twofold hours TNF infusion urokinase-type PA antigen levels plasma unaltered hours TNF infusion plasma levels alpha average fibrinolysis hours TNF infusion significant increase fibrin- fibrinogen-degradation products fibrin degradation products fibrinogen degradation products fibrinolysis presence high levels PAI activity Whereas production t-PA production human endothelial cells vitro remains unaltered decreases TNF addition TNF infusion patients results thrombin fibrin generation possible thrombin TNF actual stimulus t-PA production patients fibrin TNF infusions plasmin t-PA action initial formation soluble fibrin molecules process generation degradation products fibrin fibrinogen infusion TNF patients 